Abdominal Closure Bundle to Reduce Surgical Site Infection in Patients Undergoing C-sections. Cesarean Section Lead to Reduction in Surgical Site Infection? - A Randomized Controlled Trial
Primary Purpose
Surgical Site Infection, Cesarean Section; Infection
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Abdominal Closure Bundle
Sponsored by
About this trial
This is an interventional prevention trial for Surgical Site Infection
Eligibility Criteria
Inclusion Criteria:
- 18 years or older
- Greater than 34 weeks of gestation who will be undergoing a scheduled cesarean section to be performed by Abington Primary Women's Health Care Group, Abington Ob/Gyn Associates, Womencare, Women's Health Care Group, Dr. Ron Hoffman, or the Ob/Gyn Chief Service will be considered for participation in this study.
- Patients who present to obstetrical triage in labor or with ruptured membranes who are for cesarean section are also included in the study.
Exclusion Criteria:
- Unscheduled, STAT or urgent cesarean sections from the labor floor (failure to descend, failure to progress, non-reassuring fetal heart tracing, chorioamnionitis, placental abruption, prolapsed cord, etc.)
- SOAT (Surgical Operative Assist Team) cesarean sections
- Gestational age < 34 weeks for any reason
- Preterm premature rupture of membranes from antepartum unit
Sites / Locations
- Abington Hospital-Jefferson HealthRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Abdominal Closure Bundle
Control
Arm Description
Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin.
Normal operative procedure. The abdominal closure bundle will not be used.
Outcomes
Primary Outcome Measures
Surgical Site Infection
Definitions per 2017 CDC definitions
Secondary Outcome Measures
Risk factors for surgical site infection
Will collect demographic, obstetrical, and surgical characteristics and determine specific risk factors for surgical site infection in these patients.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03500055
Brief Title
Abdominal Closure Bundle to Reduce Surgical Site Infection in Patients Undergoing C-sections. Cesarean Section Lead to Reduction in Surgical Site Infection? - A Randomized Controlled Trial
Official Title
Does Implementation of an Abdominal Closure Bundle in Patients Undergoing Scheduled Cesarean Section Lead to Reduction in Surgical Site Infection? - A Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Unknown status
Study Start Date
June 1, 2018 (Actual)
Primary Completion Date
December 2019 (Anticipated)
Study Completion Date
December 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Abington Memorial Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study is a single center, randomized controlled trial investigating the use of an abdominal closure bundle to reduce surgical site infection in patients undergoing cesarean section. The abdominal closure bundle consists of surgeon repeat scrub, changing gown and gloves, as well as usage of new instruments for closure of fascia, subcutaneous tissue, and skin. Patients will be randomized to either abdominal closure bundle or normal operative procedure. Primary outcome is surgical site infection within 30 days of procedure.
Detailed Description
All patients, aged 18 years or older, greater than 34 weeks of gestation who will be undergoing a scheduled cesarean section to be performed by Abington Primary Women's Health Care Group, Abington Ob/Gyn Associates, Womencare, Women's Health Care Group, Dr. Ron Hoffman, or the Ob/Gyn Chief Service will be considered for participation in this study. Scheduled cesarean sections include all routine cesarean sections- whether receiving spinal or general anesthesia, as well as patients who present to obstetrical triage in labor or with ruptured membranes who are for cesarean section.
The following patients will be excluded from our study:
Unscheduled, STAT or urgent cesarean sections from the labor floor (failure to descend, failure to progress, non-reassuring fetal heart tracing, chorioamnionitis, placental abruption, prolapsed cord, etc.)
SOAT (Surgical Operative Assist Team) cesarean sections
Gestational age < 34 weeks for any reason
Preterm premature rupture of membranes from antepartum unit
As there are no published prospective trials abdominal closure bundles in cesarean sections, sample size calculations were completed using a recently published meta-analysis of multiple retrospective studies.4 These studies investigated various surgical site reduction techniques as applied to cesarean sections. Using this data, which shows an average pre-intervention SSI rate of 6% and post-reduction SSI rate of 2%, to detect a statistically significant reduction, we will need to enroll approximately 850 patients.
Patients will be randomly assigned to receive either normal operative procedure or the closing bundle through a randomized process. Simple randomization in a 1:1 ratio will be completed via Microsoft Excel. Group assignments will be placed in sealed opaque envelopes which will be located on the labor and delivery unit. The envelope will be opened by the resident physician or advanced practice professional who will be assisting with the cesarean section on arrival to the operating room. This will allow the scrub tech to prepare the closing tray prior to the start of the procedure if indicated.
All patients will receive pre-operative antibiotics, chlorhexidine abdominal preparation, thirty second betadine vaginal preparation, hair removal by clippers at the operative site, lower extremity forced air warmer, subcutaneous tissue closure >2cm, subcuticular skin closure, and removal of surgical bandage on post-operative day 2. The abdominal closure bundle includes changing of the surgical gown and gloves, repeat surgical scrub, and usage of new surgical instruments, light handles, suction, and bovie tip for closure of fascia, subcutaneous tissue, and skin. Given the nature of the intervention, the surgeon and patient will not be blinded to group assignment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Surgical Site Infection, Cesarean Section; Infection
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Single center, randomized controlled trial
Masking
InvestigatorOutcomes Assessor
Masking Description
Only the primary investigators will be able to be blinded for this study. The surgeon is unable to be blinded and since the patient is awake during c-sections, blinding will be impossible.
Allocation
Randomized
Enrollment
850 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Abdominal Closure Bundle
Arm Type
Experimental
Arm Description
Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Normal operative procedure. The abdominal closure bundle will not be used.
Intervention Type
Procedure
Intervention Name(s)
Abdominal Closure Bundle
Intervention Description
Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin
Primary Outcome Measure Information:
Title
Surgical Site Infection
Description
Definitions per 2017 CDC definitions
Time Frame
Within 30 days of procedure.
Secondary Outcome Measure Information:
Title
Risk factors for surgical site infection
Description
Will collect demographic, obstetrical, and surgical characteristics and determine specific risk factors for surgical site infection in these patients.
Time Frame
Within 30 days of procedure.
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 years or older
Greater than 34 weeks of gestation who will be undergoing a scheduled cesarean section to be performed by Abington Primary Women's Health Care Group, Abington Ob/Gyn Associates, Womencare, Women's Health Care Group, Dr. Ron Hoffman, or the Ob/Gyn Chief Service will be considered for participation in this study.
Patients who present to obstetrical triage in labor or with ruptured membranes who are for cesarean section are also included in the study.
Exclusion Criteria:
Unscheduled, STAT or urgent cesarean sections from the labor floor (failure to descend, failure to progress, non-reassuring fetal heart tracing, chorioamnionitis, placental abruption, prolapsed cord, etc.)
SOAT (Surgical Operative Assist Team) cesarean sections
Gestational age < 34 weeks for any reason
Preterm premature rupture of membranes from antepartum unit
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shaina F Bruce, MD
Phone
215-481-7915
Email
shaina.bruce@jefferson.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Preethi Rajendran, MD
Phone
215-481-7884
Email
preethi.rajendran@jefferson.edu
Facility Information:
Facility Name
Abington Hospital-Jefferson Health
City
Abington
State/Province
Pennsylvania
ZIP/Postal Code
19001
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shaina F Bruce, MD
Phone
215-481-7915
Email
shaina.bruce@jefferson.edu
First Name & Middle Initial & Last Name & Degree
Preethi Rajendran, MD
Phone
215-481-7884
Email
preethi.rajendran@jefferson.edu
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
27955845
Citation
Pellegrini JE, Toledo P, Soper DE, Bradford WC, Cruz DA, Levy BS, Lemieux LA. Consensus Bundle on Prevention of Surgical Site Infections After Major Gynecologic Surgery. J Obstet Gynecol Neonatal Nurs. 2017 Jan-Feb;46(1):100-113. doi: 10.1016/j.jogn.2016.10.003. Epub 2016 Dec 8.
Results Reference
background
PubMed Identifier
28734498
Citation
Schiavone MB, Moukarzel L, Leong K, Zhou QC, Afonso AM, Iasonos A, Roche KL, Leitao MM Jr, Chi DS, Abu-Rustum NR, Zivanovic O. Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery. Gynecol Oncol. 2017 Oct;147(1):115-119. doi: 10.1016/j.ygyno.2017.07.010. Epub 2017 Jul 19.
Results Reference
background
PubMed Identifier
25788822
Citation
Lachiewicz MP, Moulton LJ, Jaiyeoba O. Pelvic surgical site infections in gynecologic surgery. Infect Dis Obstet Gynecol. 2015;2015:614950. doi: 10.1155/2015/614950. Epub 2015 Feb 18.
Results Reference
background
PubMed Identifier
28885421
Citation
Carter EB, Temming LA, Fowler S, Eppes C, Gross G, Srinivas SK, Macones GA, Colditz GA, Tuuli MG. Evidence-Based Bundles and Cesarean Delivery Surgical Site Infections: A Systematic Review and Meta-analysis. Obstet Gynecol. 2017 Oct;130(4):735-746. doi: 10.1097/AOG.0000000000002249.
Results Reference
background
PubMed Identifier
29548786
Citation
Bruce SF, Carr DN, Burton ER, Sorosky JI, Shahin MS, Naglak MC, Edelson MI. Implementation of an abdominal closure bundle to reduce surgical site infection in patients on a gynecologic oncology service undergoing exploratory laparotomy. Gynecol Oncol. 2018 Jun;149(3):560-564. doi: 10.1016/j.ygyno.2018.03.045. Epub 2018 Mar 14.
Results Reference
background
Links:
URL
http://www.cdc.gov/nhsn/PDFs/pscManual/9pscSSIcurrent.pdf
Description
2017 CDC Surgical Site Infection Guidelines
Learn more about this trial
Abdominal Closure Bundle to Reduce Surgical Site Infection in Patients Undergoing C-sections. Cesarean Section Lead to Reduction in Surgical Site Infection? - A Randomized Controlled Trial
We'll reach out to this number within 24 hrs